Jon Gentsch (CDC)
Roger Glass (CDC)
Yuhuan Wang (CDC)
- In vitro data available
- In vivo data available (animal)
This invention relates to rotavirus vaccine compositions and methods of vaccination. Rotaviral infection is the most commonly occurring gastrointestinal illness of children world, affecting both developed and developing economies. Additionally, rotavirus infections can affect livestock (especially calves and piglets), and resulting mortality/morbidity cause major economic losses for farmers and nations each year.
The vaccine strains include Rotavirus A CDC-9 (PGl) and CDC-66 (PG2 serotype). These strains represent common rotavirus serotypes and may serve as improvements or alternatives to current live, oral rotavirus vaccine strains. Further, this technology has demonstrated efficacy in a large animal (piglets) modeling.
- Novel rotavirus vaccines
- Neonatal/childhood vaccination initiatives
- Rotavirus surveillance programs, important for both developing and developed nations
- Isolated strains are representative of those involved in community-acquired infection
- Suitable for the development of improved, broadly effective rotavirus vaccines
- Can be developed for injection and/or oral vaccine administration
- Derived vaccines may be administered alone or in combination with other vaccines